Ganoderma lucidum, commonly known as Reishi or Lingzhi, has been used in traditional Chinese medicine for centuries, particularly for liver health. Modern scientific studies have begun to validate some of these traditional uses. Several preclinical studies suggest that Ganoderma lucidum extracts possess hepatoprotective properties, attributed primarily to their polysaccharides, triterpenoids, and antioxidant compounds.

Animal studies have demonstrated that Ganoderma lucidum can reduce liver enzyme levels (such as ALT and AST), decrease lipid peroxidation, and protect against chemically-induced liver damage. The mechanisms appear to involve modulation of oxidative stress, anti-inflammatory activity, and inhibition of fibrogenesis. Some cell-culture studies also show that Ganoderma can inhibit the proliferation of hepatic stellate cells, which play a role in liver fibrosis.

However, well-designed clinical trials in humans are limited. A few small human studies have reported beneficial effects on liver enzyme levels and subjective symptoms in patients with hepatitis B or other liver disorders, but the evidence is not yet robust or conclusive. Therefore, while there is moderate scientific evidence from preclinical research and early clinical data supporting Ganoderma's role in liver health, more rigorous human trials are required to confirm its efficacy and safety.